Pioglitazone seems safe and effective for patients with fatty liver disease and diabetesBMJ 2016; 353 doi: https://doi.org/10.1136/bmj.i3435 (Published 21 June 2016) Cite this as: BMJ 2016;353:i3435
- Jacqui Wise
Long term use of pioglitazone seems to be safe and effective for patients with both fatty liver disease and pre-diabetes or type 2 diabetes mellitus, a randomised controlled trial published in the Annals of Internal Medicine has shown.1
Non-alcoholic fatty liver disease is a growing global public health problem and is now the most common cause of chronic liver disease in industrialised countries. Its prevalence has increased along with the dramatic rise in obesity and type 2 diabetes, and it is estimated to occur in more than 30% of the adult US population. Most of these patients have simple steatosis and …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial